We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OGEN Oragenics Inc

-0.12 (-3.35%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 7,991
Bid Price
Ask Price
News (1)
Day High 3.80


52 Week Range


Day Low 3.4662
Company Name Stock Ticker Symbol Market Type
Oragenics Inc OGEN AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -3.35% 3.46 16:15:00
Open Price Low Price High Price Close Price Prev Close
3.59 3.4662 3.80 3.46 3.58
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
200 7,991 $ 3.64 $ 29,084 - 2.58 - 12.3299
Last Trade Time Type Quantity Stock Price Currency
20:00:00 104 $ 3.46 USD

Oragenics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 8.89M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Oragenics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OGEN Message Board. Create One! See More Posts on OGEN Message Board See More Message Board Posts

Historical OGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.483.803.443.614,917-0.02-0.57%
1 Month3.883.923.443.664,145-0.42-10.82%
3 Months3.204.002.753.2516,5820.268.12%
6 Months2.914.482.653.3513,2160.5518.9%
1 Year11.7012.32992.588.14184,022-8.24-70.43%
3 Years25.80108.002.5849.353,725,321-22.34-86.59%
5 Years92.40127.202.5849.863,220,572-88.94-96.26%

Oragenics Description

Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |